---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-030447"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2024-06-18T23:59:59+00:00"
generated_at: "2026-06-01T04:00:46.968699+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ionis expands Otsuka license for donidalorsen in Asia-Pacific; $20M upfront

## Summary
- Otsuka gains exclusive rights to commercialize donidalorsen (HAE) in Asia-Pacific; Ionis retains US rights.
- Ionis receives $20M upfront, plus milestone payments and tiered royalties similar to the Europe deal.
- Ionis plans to file U.S. NDA for donidalorsen in 2024 and launch independently if approved.
- Otsuka will handle Asia-Pacific and Europe regulatory filings and commercialization; Ionis leads global development.
- Positive Phase 3 OASIS-HAE and OASISplus results were recently published in NEJM.

## SEC filing metadata
- accession: 0001140361-24-030447
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2024-06-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036124030447/0001140361-24-030447-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036124030447/ef20031301_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-030447
- JSON: https://secwatch.observer/filing/0001140361-24-030447.json
- Plain text: https://secwatch.observer/filing/0001140361-24-030447.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.